ProQR Therapeutics NV - PRQR Earnings growth forecast for next year
The development of ProQR Therapeutics N.V. (PRQR) depends on partner milestone payments, which confirms the promising growth trajectory for EPS on this GURU.Markets platform chart, where the -12.90 level indicates the parameter's status. Revenues are based on Axiomer for the treatment of liver and eye diseases, while flexible management focuses on the most promising niches with a high probability of approval.
ProQR (PRQR) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- issuer market value details:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
- net income and valuation ratios data:
PRQR - Net Financial Result|Projected Future Earnings ProQR Therapeutics N.V.|PRQR - Price to Earnings Ratio|Future Price to Earnings ProQR Therapeutics|PRQR - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio ProQR Therapeutics NV|PRQR - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months ProQR Therapeutics N.V.|PRQR - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months proqr.com|PRQR - Expected net earnings per share growth this year|Expected earnings per share growth for next year ProQR Therapeutics N.V.
- sales and revenue indicators:
Fundamental company analysis:proqr.com
Assessing the financial stability of ProQR Therapeutics N.V. (PRQR) requires an analysis of future profitability prospects. This indicator reflects the analysts' consensus forecast for the year-over-year growth rate of net earnings per share. The expected EPS trajectory for the next 12 months visualizes the dynamics of future cash flows. For a company in the clinical development stage, this metric depends directly on the probability of receiving payments from strategic partnerships.
Main competitors
TEM (Tempus) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year QGEN (Qiagen)|Earnings growth forecast for next year IONS|RGEN (Repligen) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year aviditybiosciences.com RNA|CRISPR (CRSP) - Expected net earnings per share growth next year|genedx.com - Earnings growth forecast for next year|Expected earnings per share trend next year RARE (ultragenyx.com)|BEAM: Earnings growth forecast for next year|Sarepta - Expected earnings per share trend next year|TWST (twistbioscience.com) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year TXG (10x Genomics Corp)|Earnings growth forecast for next year NTLA|Earnings growth forecast for next year Stoke Therapeutics, Inc. (STOK)|Net earnings per share growth forecast for next year BioLife BLFS|WVE - Expected earnings per share growth for next year|Maze Therapeutics Corp - Earnings growth forecast for next year|Sionna Pharma - Projected earnings per share increase next year|Prime Medicine (PRME) - Net earnings per share growth forecast for next year|tayshagtx.com (TSHA) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year uniQure Corp|MGTX: Expected earnings per share trend next year|Earnings growth forecast for next year RGNX|Consensus forecast of earnings per share growth for next year Solid Corp|Earnings growth forecast for next year OCGN (ocugen.com)|PACB (Pacific Biosciences) - Net earnings per share change forecast for next year|Benitec Biopharma Inc - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Design Therapeutics, Inc. DSGN|Rocket Corp (RCKT) - Net earnings per share growth forecast for next year|4D Molecular Therapeutics (FDMT) - Earnings growth forecast for next year|LXEO (Lexeo Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year korrobio.com KRRO|Expected earnings per share growth for next year EDIT (Editas Medicine, Inc.)|Silence Therapeutics plc - Projected earnings per share growth rate for next year|Earnings growth forecast for next year CDXS (codexis.com)|SGMO: Projected earnings per share growth rate for next year|NAUT: Expected earnings per share growth for next year|Expected net earnings per share growth next year metagenomi.co|Precision BioSciences, Inc. (DTIL) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Generation Bio Corp (GBIO)|Expected earnings per share growth for next year BOLD|exicuretx.com (XCUR) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year IMNN (Celsion Corporation)|PHIO (Phio Pharmaceuticals Corp.) - Expected earnings per share trend next year|Earnings growth forecast for next year MBIO (Mustang Bio Corp)|Projected earnings per share increase next year RNAZ (TransCode Therapeutics)|BNGO - Net earnings per share growth forecast for next year|APDN: Net earnings per share growth forecast for next year|BLUE: Earnings growth forecast for next year|Expected earnings per share growth for next year ImmunoPrecise Antibodies|OMGA (Omega Therapeutics, Inc.) - Earnings growth forecast for next year|Singular Genomics (OMIC) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Regulus (RGLS)|SYRS (Syros Pharmaceuticals, Inc) - Expected earnings per share trend next year|Telesis Bio, Inc. - Expected earnings per share growth for next year|TCON: Projected earnings per share growth rate for next year|Unity Biotechnology Inc. - Earnings growth forecast for next year
